Roche plans to regroup on its $4.3 billion offer to buy Spark Therapeutics after failing to win enough Spark shareholder votes, or receiving U.S. regulatory approval.
The stock surges on 'encouraging' results from a genome-therapy trial for the treatment of a severe type of hemophilia.
The myriad names in oncology have been the hottest area for acquisitions along with gene therapy.
The company's treatment, filgotinib, is being developed with Gilead Sciences.
The American Diabetes Association adds Amarin's Vascepa drug to its standard of care recommendation list.
Biogen's board approves a share buyback program days after revealing a phase III trial of a promising Alzheimer's drug is being shelved.
Thermo Fisher Scientific reaches a deal to buy closely held Brammer Bio, a leader in viral vector manufacturing for gene and cell therapies.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.